Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Glioblastoma 2Thrombocythemia, Essential 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Renal Insufficiency 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pathologic Complete Response 1Neoplasms, Unknown Primary 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lung Neoplasms 1Liver Failure 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Hemangiosarcoma 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1

Interventions

Temozolomide 42Magnetic Resonance Spectroscopy 41Radiotherapy 22Specimen Handling 18Biopsy 13X-Rays 10Radiation 10trametinib 8Bevacizumab 8Nivolumab 7Blood Specimen Collection 7olaparib 6fluorodopa F 18 6dabrafenib 6Radiotherapy, Intensity-Modulated 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Lomustine 6pembrolizumab 5abemaciclib 5Standard of Care 5vorasidenib 4ulixertinib 4larotrectinib 4ivosidenib 4erdafitinib 4Surgical Procedures, Operative 4Dianhydrogalactitol 4Cyclophosphamide 4Aminolevulinic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × veliparib × 1 year × Clear all
NCT03581292 2026-05-27

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 13 charts
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡